Recently, a clinical study showed that there are no beneficial effects of anti-TNF agent use for development of cirrhosis, non-alcoholic fatty liver disease (NAFLD) or NASH in patients with immune-related diseases (25). Here, TNF is linked to metabolic dysfunction-associated steatotic liver disease.